PharmAust Ltd - PAA share price
About
PharmAust Limited is an Australian clinical-stage biotechnology company that focuses on developing therapeutics for various conditions, including cancer, neurodegenerative diseases, viral infections in humans, and cancer in animals. Their lead candidate, Monepantel (MPL), is an inhibitor of the mTOR pathway, a pathway with significant implications for cancer growth and neurodegenerative diseases. MPL has undergone Phase I clinical trials in humans and Phase II clinical trials in dogs. Additionally, the company has initiated a preclinical program to evaluate the anticancer properties of its portfolio of aminoacetonitrile (AAD) compounds. PharmAust Limited's wholly-owned subsidiary, Epichem Pty Ltd, is also involved in advancing waste conversion and re-purposing technology known as Oxidative Hydrothermal Dissolution (OHD).
Company Profile
Disclaimer: The above financial data is sourced from EODHD and is for informational purposes only. Veye does not guarantee the accuracy or completeness of this data. Investors should conduct their own research and consult with a financial advisor before making investment decisions.
Price Summary
Price Chart
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Reports from Veye
Grab Your FREE Report on Top 5 ASX Stocks to Buy in 2026
Latest Article
